Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 17 results for "ajanta pharma"

Ajanta Pharma - Income from Operations up 11%, PAT up 5% in Q4...

Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 4th quarter and financial year ended 31st March 2017. Tweet Mumbai, Maharashtra, May 10, 2017 / India PRwire/ -- Ajanta Pharma Ltd. a specialty ... India PRwire, 1 month ago
Ajanta Pharma to hold AGM Business Standard, 1 month ago

39 images for ajanta pharma

Money Control, 2 weeks ago
Money Control, 3 weeks ago
Money Control, 1 week ago
Money Control, 1 month ago
Money Control, 2 months ago
Money Control, 1 month ago
Money Control, 2 months ago
Money Control, 2 months ago
Money Control, 1 month ago
Money Control, 1 month ago
Money Control

USFDA completes inspection of Dahej unit: Ajanta Pharma

Drug firm Ajanta Pharma today said the US health regulator has successfully completed inspection of its Dahej facility.
 DNA2 months ago Ajanta Pharma rises after USFDA clears Dahej facility  Business Standard2 months ago Ajanta Pharma intimates of successful inspection of its facility at Dahej  Business Standard2 months ago Ajanta Pharma soars after US FDA issues no observations at Dahej plant  Money Control2 months ago

Resistance for Nifty at 9300-9414; buy Ajanta Pharma: Prakash Gaba

Prakash Gaba of prakashgaba.com is of the view that Nifty has support at 9200 and resistance at 9300-9414 while Bank Nifty has support at 21500 and resistance at 22000.
 Money Control2 months ago
Money Control

4 stocks that delivered over 30% returns on equity capital in the past 3 years

Ajanta Pharma, Bajaj Corp, Hero Motocorp and TCS were the exceptional performers.
 Money Control1 month ago
Rediff.com

Note ban shadow lingers over one in four BSE 200 stocks

Quite a few large- and mid-cap stocks are yet to recover from the note ban, pharma, banking and rural demand-based industries among laggards. The S&P BSE Sensex may have recovered from demonetisation to touch a new high of 29,649 points recently, but quite a few large- and mid-cap stocks are yet to recover from the note ban. Nearly 28% of the BSE 200 stocks trade below their November 8, 2016, levels. These include IDFC Bank, Dr Reddy’s Laboratories, Reliance Communications, United ...
 Rediff.com2 months ago
Rediff.com

Mid-cap selloff: Don't press the panic button, say experts

Despite the recent fall, the Nifty Midcap 100 index has outperformed by gaining 20 per cent till date, experts tell Puneet Wadhwa and Deepak Korgaonkar The Nifty Midcap 100 index hit a two-month low of 17,039 on the National Stock Exchange in intra-day trade last week, but managed to recoup losses to end one per cent higher at 17,412. The Nifty Midcap 100 index has underperformed the market, falling 5.9 per cent from its all-time high closing level of 18,948 on May 16. In comparison, the Nifty ...
 Rediff.com2 weeks ago
Sify

Week Ahead: Quarterly results, sales & shipments data from auto, cement makers to set the trend

The Indian stock market is likely to track quarterly earnings reports, global trend and movements of the rupee and crude oil for direction in the coming week, which will be a short one due to a holiday on Monday (May 1) for Maharashtra Day. ICICI Bank, HDFC, ...
 Sify1 month ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less